Radiotherapy for pathological stage Ia and IIa (Upper) Hodgkin's disease

ISRCTN ISRCTN98387311
DOI https://doi.org/10.1186/ISRCTN98387311
Secondary identifying numbers HD1-82
Submission date
01/07/2001
Registration date
01/07/2001
Last edited
01/02/2012
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Study designNon randomised trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study objectivesNot provided at time of registration
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedLymphoma (Hodgkin's)
InterventionThis is a non randomised study, patients are grouped according to site and stage of disease:

1. Group A: Patients with pathological stage Ia (neck), IIa (neck) and Ia (axilla) are assigned to local field radiotherapy. Patients with neck disease receive 30 Gy midline in sixteen fractions over 3 weeks followed by an additional 5 Gy to the site of palpable disease. Patients with axillary disease receive 35 Gy midline in sixteen fractions over 3 weeks.

2. Group B: Patients with pathological stage Ia (supraclavicular), IIa (all sites except neck) are assigned to mantle radiotherapy. Patients receive a dose of 35 Gy mid line in twenty fractions over 4 weeks followed by an additional 6 Gy to the anterior mediastinum.
Intervention typeOther
Primary outcome measureNot provided at time of registration
Secondary outcome measuresNot provided at time of registration
Overall study start date01/01/1998
Completion date31/12/2001

Eligibility

Participant type(s)Patient
Age groupAdult
SexNot Specified
Target number of participantsNot provided at time of registration
Key inclusion criteria1. Pathological stage Ia and IIa (upper) Hodgkin's disease
2. Aged 15 to 65 years
Key exclusion criteriaPatients with mediastinal disease will not in general be eligible for local radiotherapy alone
Date of first enrolment01/01/1998
Date of final enrolment31/12/2001

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Phone +44 (0)207 317 5186
Email kate.law@cancer.org.uk
Website http://www.cancer.org.uk
ROR logo "ROR" https://ror.org/054225q67

Funders

Funder type

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations
Alternative name(s)
CR_UK, Cancer Research UK - London, CRUK
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/02/2005 Yes No